More anecdotal evidence as to the effectiveness of
Post# of 148275
The big question for investors is whether the Philippines FDA, and other global FDA's, will issue EUA's given that there is little risk in doing so as Leronlimab has not resulted in any serious adverse events in the treatment of over 1,000 patients for Covid, cancer, and HIV.